# Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

> **NCT00454298** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 2 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** AGG-523 (Aggrecanase Inhibitor)

## Key facts

- **NCT ID:** NCT00454298
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2009-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454298, "Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00454298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*